Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
World Journal of Urology
Published in: World Journal of Urology 5/2006

01-11-2006 | Topic paper

Chemoprevention of bladder cancer

Authors: Dragan J. Golijanin, David Kakiashvili, Ralph R. Madeb, Edward M. Messing, Seth P. Lerner

Published in: World Journal of Urology | Issue 5/2006

Login to get access

Excerpt

Primary prevention
  • Stop the exposure or remove the risk factors
Secondary prevention
  • Early detection and intervention/chemoprevention in high risk populations
Tertiary prevention
  • Treatment to prevent recurrences, disease progression and complications
…
Literature
1.
JemalA, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ (2004) Cancer statistics, 2004. CA Cancer J Clin 54(1):8 PM:14974761
2.
SilverbergE, Cancer statistics, 1985. CA Cancer J Clin 35(1):19 PM:3917839
3.
KishiK, Hirota T, Matsumoto K, Kakizoe T, Murase T, Fujita J (1981) Carcinoma of the bladder: a clinical and pathological analysis of 87 autopsy cases. J Urol 125(1):36 PM:7463579
4.
LynchCF, Cohen MB (1995) Urinary system. Cancer, 75(1 Suppl):316 PM:8001003
5.
MadebR, Messing EM (2004) Gender, racial and age differences in bladder cancer incidence and mortality. Urol Oncol 22(2):86 PM:15082003
6.
MunganNA, Kiemeney LA, van Dijck JA, van der Poel HG, Witjes JA (2000) Gender differences in stage distribution of bladder cancer. Urology 55(3):368 PM:10699612
7.
Rehn L (1895) Ueber blasentrumoren bei fuchsinarbeitern. Arch Kind Chir 50:588
8.
MorrisonAS, Cole P (1976) Epidemiology of bladder cancer. Urol Clin North Am 3(1):13 PM:936365
9.
SteineckG, Plato N, Norell SE, Hogstedt C (1990) Urothelial cancer and some industry-related chemicals: an evaluation of the epidemiologic literature. Am J Ind Med 17(3):371 PM:2407118
10.
Stadler WM (1993) Molecular events in the initiation and progression of bladder cancer. Int J Oncol 3:549
11.
Case RA, Hosker ME, McDonald DB, Pearson JT (1954) Tumours of the urinary bladder in workmen engaged in the manufacture and use of certain dyestuff intermediates in the British chemical industry. I. The role of aniline, benzidine, alpha-naphthylamine, and beta-naphthylamine. Br J Ind Med 11(2):75 PM:13149741
12.
Cole P, Hoover R, Friedell GH (1972) Occupation and cancer of the lower urinary tract. Cancer 29(5):1250 PM:5021618
13.
Chapman JW, Connolly JG, Rosenbaum L, Connolly JG (1981) Occupational bladder cancer: a case-control study, in carcinoma of the bladder. Raven Press, New York, p 45
14.
Nortier JL, Martinez MC, Schmeiser HH, Arlt VM, Bieler CA, Petein M, Depierreux MF, De PL, Abramowicz D, Vereerstraeten P, Vanherweghem JL (2000) Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 342(23):1686 PM:10841870
15.
Malker HS, McLaughlin JK, Silverman DT, Ericsson JL, Stone BJ, Weiner JA, Malker BK, Blot WJ (1987) Occupational risks for bladder cancer among men in Sweden. Cancer Res 47(24 Pt 1):6763 PM:3677105
16.
Silverman DT, Levin LI, Hoover RN, Hartge P (1989) Occupational risks of bladder cancer in the United States: I. White men. J Natl Cancer Inst 81(19):1472 PM:2778834
17.
Silverman DT, Levin LI, Hoover RN (1989) Occupational risks of bladder cancer in the United States: II Nonwhite men. J Natl Cancer Inst 81(19):1480 PM:2778835
18.
Burch JD, Rohan TE, Howe GR, Risch HA, Hill GB, Steele R, Miller AB (1989) Risk of bladder cancer by source and type of tobacco exposure: a case-control study. Int J Cancer 44(4):622 PM:2793235
19.
Morrison AS (1984) Advances in the etiology of urothelial cancer. Urol Clin North Am 11(4):557 PM:6506370
20.
Hoffman D, Masuda Y, Wynder EL (1969) Alpha-naphthylamine and beta-naphthylamine in cigarette smoke. Nature 221(177):255 PM:5763078
21.
Howe GR, Burch JD, Miller AB, Cook GM, Esteve J, Morrison B, Gordon P, Chambers LW, Fodor G, Winsor GM (1980) Tobacco use, occupation, coffee, various nutrients, and bladder cancer. J Natl Cancer Inst 64(4):701 PM:6928984
22.
Paz A, Cytron S, Lobek L (2002) Passive smoking - a risk factor for transitional carcinoma of the bladder in patients with hematuria. J Urol 167:161
23.
AugustineA, Hebert JR, Kabat GC, Wynder EL (1988) Bladder cancer in relation to cigarette smoking. Cancer Res 48(15):4405 PM:3390836
24.
Fleshner N, Garland J, Moadel A, Herr H, Ostroff J, Trambert R, O’Sullivan M, Russo P (1999) Influence of smoking status on the disease-related outcomes of patients with tobacco-associated superficial transitional cell carcinoma of the bladder. Cancer 86(11):2337 PM:10590376
25.
Thompson RA Jr, Campbell EW Jr, Kramer HC, Jacobs SC, Naslund MJ (1993) Late invasive recurrence despite long-term surveillance for superficial bladder cancer. J Urol 149(5):1010 PM:8483201
26.
Kantor AF, Hartge P, Hoover RN, Narayana AS, Sullivan JW, Fraumeni JF Jr (1984) Urinary tract infection and risk of bladder cancer. Am J Epidemiol 119(4):510 PM:6711540
27.
Locke JR, Hill DE, Walzer Y (1985) Incidence of squamous cell carcinoma in patients with long-term catheter drainage. J Urol 133(6):1034 PM:3999203
28.
Pannek J (2002) Transitional cell carcinoma in patients with spinal cord injury: a high risk malignancy? Urology 59(2):240 PM:11834395
29.
Messing EM, Young TB, Hunt VB, Gilchrist KW, Newton MA, Bram LL, Hisgen WJ, Greenberg EB, Kuglitsch ME, Wegenke JD (1995) Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. Urology 45(3):387 PM:7879333
30.
Bahnson RR (1997) Squamous cell carcinoma of bladder. J Urol 157(6):2115 PM:9146594
31.
Hamid, R, Bycroft J, Arya M, Shah PJ (2003) Screening cystoscopy and biopsy in patients with neuropathic bladder and chronic suprapubic indwelling catheters: is it valid? J Urol 170(2 Pt 1):425 PM:12853791
32.
Tricker AR, Mostafa MH, Spiegelhalder B, Preussmann R (1989) Urinary excretion of nitrate, nitrite and N-nitroso compounds in Schistosomiasis and bilharzia bladder cancer patients. Carcinogenesis 10(3):547 PM:2924399
33.
Higgy NA, Verma AK, Erturk E, Bryan GT (1985) Augmentation of N-butyl-N-(4-hydroxybutyl) nitrosamine (BHBN) bladder carcinogenicity in Fischer 344 female rats by urinary infection. Proc Annu Meet Am Assoc Cancer Res 26:118
34.
Aynaud O, Tranbaloc P, Orth G (1998) Lack of evidence for a role of human papillomaviruses in transitional cell carcinoma of the bladder. J Urol 159(1):86 PM:9400443
35.
Maloney KE, Wiener JS, Walther PJ (1994) Oncogenic human papillomaviruses are rarely associated with squamous cell carcinoma of the bladder: evaluation by differential polymerase chain reaction. J Urol 151(2):360 PM:8283525
36.
Noel JC, Thiry L, Verhest A, Deschepper N, Peny MO, Sattar AA, Schulman CC, Haot J (1994) Transitional cell carcinoma of the bladder: evaluation of the role of human papillomaviruses. Urology 44(5):671 PM:7974942
37.
LaRue H, Simoneau M, Fradet Y (1995) Human papillomavirus in transitional cell carcinoma of the urinary bladder. Clin Cancer Res 1(4):435 PM:9816001
38.
Griffiths TR, Mellon JK (2000) Human papillomavirus and urological tumours: II. Role in bladder, prostate, renal and testicular cancer. BJU Int 85(2):211 PM:10671869
39.
Fraley EE, Skinner DG, de Kernion JB (1978) Cancer of the renal pelvis, in Genitourinary cancer, WB Saunders, Philadelphia, p 134
40.
Duncan RE, Bennett DW, Evans AT, Aron BS, Schellhas HF (1977) Radiation-induced bladder tumors. J Urol 118(1 Pt 1):43 PM:875195
41.
Kaldor JM, Day NE, Kittelmann B, Pettersson F, Langmark F, Pedersen D, Prior P, Neal F, Karjalainen S, Bell J (1995) Bladder tumours following chemotherapy and radiotherapy for ovarian cancer: a case-control study. Int J Cancer 63(1):1 PM:7558434
42.
Quilty PM, Kerr GR (1987) Bladder cancer following low or high dose pelvic irradiation. Clin Radiol 38(6):583 PM:3690959
43.
Brenner DJ, Curtis RE, Hall EJ, Ron E (2000) Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer 88(2):398 PM:10640974
44.
Brenner DJ, Hall EJ, Curtis RE, Ron E (2005) Prostate radiotherapy is associated with second cancers in many organs, not just the colorectum. Gastroenterology 129(2):773 PM:16083746
45.
Neugut AI, Ahsan H, Robinson E, Ennis RD (1997) Bladder carcinoma and other second malignancies after radiotherapy for prostate carcinoma. Cancer 79(8):1600 PM:9118045
46.
PicklesT, Phillips N (2002) The risk of second malignancy in men with prostate cancer treated with or without radiation in British Columbia, 1984–2000. Radiother Oncol 65(3):145 PM:12464442
47.
Sandhu JS, Vickers AJ, Bochner B, Donat SM, Herr HW, Dalbagni G (2006) Clinical characteristics of bladder cancer in patients previously treated with radiation for prostate cancer. BJU Int 98(1):59 PM:16626308
48.
Romanenko A, Morimura K, Wei M, Zaparin W, Vozianov A, Fukushima S (2002) DNA damage repair in bladder urothelium after the Chernobyl accident in Ukraine. J Urol 168(3):973 PM:12187202
49.
Romanenko A, Morimura K, Wanibuchi H, Wei M, Zaparin W, Vinnichenko W, Kinoshita A, Vozianov A, Fukushima S (2003) Urinary bladder lesions induced by persistent chronic low-dose ionizing radiation. Cancer Sci 94(4):328 PM:12824899
50.
Cohen SM, Garland EM, J. M St, Okamura T, Smith RA (1992) Acrolein initiates rat urinary bladder carcinogenesis. Cancer Res 52(13):3577 PM:1617627
51.
Vlaovic P, Jewett MA (1999) Cyclophosphamide-induced bladder cancer. Can J Urol 6(2):745 PM:11178599
52.
Habs MR, Schmahl D (1983) Prevention of urinary bladder tumors in cyclophosphamide-treated rats by additional medication with the uroprotectors sodium 2-mercaptoethane sulfonate (mesna) and disodium 2,2′-dithio-bis-ethane sulfonate (dimesna). Cancer 51(4):606 PM:6401591
53.
Pedersen-Bjergaard J, Ersboll J, Hansen VL, Sorensen BL, Christoffersen K, Hou-Jensen K, Nissen NI, Knudsen JB, Hansen MM (1988) Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin’s lymphoma. N Engl J Med 318(16):1028 PM:3352696
54.
Fernandes ET, Manivel JC, Reddy PK, Ercole CJ (1996) Cyclophosphamide associated bladder cancer–a highly aggressive disease: analysis of 12 cases. J Urol 156(6):1931 PM:8911359
55.
Liou SH, Lung JC, Chen YH, Yang T, Hsieh LL, Chen CJ, Wu TN (1999) Increased chromosome-type chromosome aberration frequencies as biomarkers of cancer risk in a blackfoot endemic area. Cancer Res 59(7):1481 PM:10197617
56.
Moore LE, Smith AH, Hopenhayn-Rich C, Biggs ML, Kalman DA, Smith MT (1997) Decrease in bladder cell micronucleus prevalence after intervention to lower the concentration of arsenic in drinking water. Cancer Epidemiol Biomarkers Prev 6(12):1051 PM:9419402
57.
Vanhaelen M, Vanhaelen-Fastre R, But P, Vanherweghem JL (1994) Identification of aristolochic acid in Chinese herbs. Lancet 343(8890):174 PM:7904018
58.
Kessler DA (2000) Cancer and herbs. N Engl J Med 342(23):1742 PM:10841878
59.
Buzzeo BD, Heisey DM, Messing EM (1997) Bladder cancer in renal transplant recipients. Urology 50(4):525 PM:9338726
60.
Michaud DS, Spiegelman D, Clinton SK, Rimm EB, Curhan GC, Willett WC, Giovannucci EL (1999) Fluid intake and the risk of bladder cancer in men. N Engl J Med 340(18):1390 PM:10228189
61.
Penn I (1988) Secondary neoplasms as a consequence of transplantation and cancer therapy. Cancer Detect Prev 12(1-6):39 PM:3052837
62.
Kiemeney LA, Schoenberg M (1996) Familial transitional cell carcinoma. J Urol 156(3):867 PM:8709350
63.
Aherne G (1974) Retinoblastoma associated with other primary malignant tumours. Trans Ophthalmol Soc UK 94(4):938 PM:4534143
64.
Kiemeney LA, Moret NC, Witjes JA, Schoenberg MP, Tulinius H (1997) Familial transitional cell carcinoma among the population of Iceland. J Urol 157(5):1649 PM:9112497
65.
Lynch HT, Kimberling WJ, Lynch JF, Brennan K (1987) Familial bladder cancer in an oncology clinic. Cancer Genet Cytogenet 27(1):161 PM:3581037
66.
Lynch HT, Ens JA, Lynch JF (1990) The Lynch syndrome II and urological malignancies. J Urol 143(1):24 PM:2294255
67.
McCullough DL, Lamma DL, McLaughlin AP III, Gittes RF (1975) Familial transitional cell carcinoma of the bladder. J Urol 113(5):629 PM:1127804
68.
Kantor AF, Hartge P, Hoover RN, Fraumeni JF Jr (1985) Familial and environmental interactions in bladder cancer risk. Int J Cancer 35(6):703 PM:4008097
69.
Thorstenson A, Larsson H, Wijkstrom H et al (2003) Bladder cancer characteristics in a population based study of newly detected tumors. J Urol 169
70.
Althausen AF, Prout GR Jr, Daly JJ (1976) Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. J Urol 116(5):575 PM:978809
71.
Prout GR Jr, Barton BA, Griffin PP, Friedell GH (1992) Treated history of noninvasive grade 1 transitional cell carcinoma. The National Bladder Cancer Group. J Urol 148(5):1413 PM:1433540
72.
Lutzeyer, W, Rubben H, Dahm H (1982) Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. J Urol 127(2):250 PM:7062375
73.
Cookson MS, Sarosdy MF (1992) Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy. J Urol 148(3):797 PM:1512829
74.
Freeman JA, Esrig D, Stein JP, Simoneau AR, Skinner EC, Chen SC, Groshen S, Lieskovsky G, Boyd SD, Skinner DG (1995) Radical cystectomy for high risk patients with superficial bladder cancer in the era of orthotopic urinary reconstruction. Cancer 76(5):833 PM:8625187
75.
Norming U, Tribukait B, Gustafson H, Nyman CR, Wang NN, Wijkstrom H (1992) Deoxyribonucleic acid profile and tumor progression in primary carcinoma in situ of the bladder: a study of 63 patients with grade 3 lesions. J Urol 147(1):11 PM:1729494
76.
Herr HW, Donat SM, Dalbagni G (2002) Correlation of cystoscopy with histology of recurrent papillary tumors of the bladder. J Urol 168(3):978 PM:12187203
77.
Cheng L, Neumann RM, Bostwick DG (1999) Papillary urothelial neoplasms of low malignant potential. Clinical and biologic implications. Cancer 86(10):2102 PM:10570438
78.
Holmang S, Hedelin H, Anderstrom C, Johansson SL (1995) The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J Urol 153(6):1823 PM:7752327
79.
Borhan A, Reeder JE, O’Connell MJ, Wright KO, Wheeless LL, di Sant’Agnese PA, McNally ML, Messing EM (2003) Grade progression and regression in recurrent urothelial cancer. J Urol 169(6):2106 PM:12771728
80.
Golijanin D, Sherman Y, Shapiro A, Pode D (1995) Detection of bladder tumors by immunostaining of the Lewis X antigen in cells from voided urine. Urology 46(2):173 PM:7624989
81.
Hayes RB, Friedell GH, Zahm SH, Cole P (1993) Are the known bladder cancer risk-factors associated with more advanced bladder cancer? Cancer Causes Control 4(2):157 PM:8481494
82.
Messing EM (1990) Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma. Cancer Res 50(8):2530 PM:1690599
83.
Rao JY, Hemstreet GP III, Hurst RE, Bonner RB, Jones PL, Min KW, Fradet Y (1993) Alterations in phenotypic biochemical markers in bladder epithelium during tumorigenesis. Proc Natl Acad Sci USA 90(17):8287 PM:8367495
84.
Sheinfeld J, Reuter VE, Melamed MR, Fair WR, Morse M, Sogani PC, Herr HW, Whitmore WF, Cordon -Cardo C (1990) Enhanced bladder cancer detection with the Lewis X antigen as a marker of neoplastic transformation. J Urol 143(2):285 PM:2405185
85.
Tsai YC, Nichols PW, Hiti AL, Williams Z, Skinner DG, Jones PA (1990) Allelic losses of chromosomes 9, 11, and 17 in human bladder cancer. Cancer Res 50(1):44 PM:2293558
86.
Chi-Wei L, Zhang DS, Kwiatkowski DJ et al (1995) Potential location of a bladder tumor suppressor gene on chromosome 9q at 9q13 to 9q22.1. Urol Oncol 1:88
87.
Hernandez S, Lopez-Knowles E, Lloreta J, Kogevinas M, Amoros A, Tardon A, Carrato A, Serra C, Malats N, Real FX (2006) Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol 24(22):3664 PM:16877735
88.
Feldman AR, Kessler L, Myers MH, Naughton MD (1986) The prevalence of cancer. Estimates based on the Connecticut Tumor Registry. N Engl J Med 315(22):1394 PM:3773965
89.
Zeegers MP, Goldbohm RA, van den Brandt PA (2002) A prospective study on active and environmental tobacco smoking and bladder cancer risk (The Netherlands). Cancer Causes Control 13(1):83 PM:11899922
90.
Alpha-Tocopherol BC.C.P.S.G (1994) The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 330(15):1029 PM:8127329
91.
Environmental Protection A. (2001) Federal Regulation 66 (no. 14). National primary drinking water regulations: arsenic and clarifications to compliance and new source contaminants monitoring; final rule. 14. EPA 2001
92.
Morales KH, Ryan L, Kuo TL, Wu MM, Chen CJ (2000) Risk of internal cancers from arsenic in drinking water. Environ Health Perspect 108(7):655 PM:10903620
93.
Chen CJ, Chuang YC, Lin TM, Wu HY (1985) Malignant neoplasms among residents of a blackfoot disease-endemic area in Taiwan: high-arsenic artesian well water and cancers. Cancer Res 45(11 Pt 2):5895 PM:4053060
94.
Chen CJ, Chuang YC, You SL, Lin TM, Wu HY (1986) A retrospective study on malignant neoplasms of bladder, lung and liver in blackfoot disease endemic area in Taiwan. Br J Cancer 53(3):399 PM:3964542
95.
Chiou HY, Chiou ST, Hsu YH, Chou YL, Tseng CH, Wei ML, Chen CJ (2001) Incidence of transitional cell carcinoma and arsenic in drinking water: a follow-up study of 8,102 residents in an arseniasis-endemic area in northeastern Taiwan. Am J Epidemiol 153(5):411 PM:11226969
96.
Yang CY, Chiu HF, Chang CC, Ho SC, Wu TN (2005) Bladder cancer mortality reduction after installation of a tap-water supply system in an arsenious-endemic area in southwestern Taiwan. Environ Res 98(1):127 PM:15721893
97.
Meyskens FL, Szabo E (2005) How should we move the field of chemopreventive agent development forward in a productive manner? Recent Results Cancer Res 166: 113 PM:15648187
98.
Papadimitrakopoulou VA, Hong WK (2000) Biomolecular markers as intermediate end points in chemoprevention trials of upper aerodigestive tract cancer. Int J Cancer 88(6):852 PM:11093804
99.
Lee JS, Kurie JM, Mao L, Morice RC, Ro JY, Lippman SM, Lotan R, Hittelman WN, Hong WK (1997) Intermediate end point markers in chemoprevention trials of lung cancer. Lung Cancer 18(supplement 2):88–89
100.
Stanton AL, Bernaards CA, Ganz PA (2005) The BCPT symptom scales: a measure of physical symptoms for women diagnosed with or at risk for breast cancer. J Natl Cancer Inst 97(6):448 PM:15770009
101.
Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352(11):1092 PM:15713943
102.
Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352(11):1071 PM:15713944
103.
Negri E, LVC (ed) (2001) Epidemiology and prevention of bladder cancer
104.
Shinka T, Sawada Y, Morimoto S, Fujinaga T, Nakamura J, Ohkawa T (1991) Clinical study on urothelial tumors of dye workers in Wakayama City. J Urol 146(6):1504–1507PubMed
105.
Silverman DT, Levin LI, Hoover RN (1989) Occupational risks of bladder cancer in the United States: II Nonwhite men. J Natl Cancer Inst 81(19):1480–1483PubMed
106.
Silverman DT, Levin LI, Hoover RN, Hartge P (1989) Occupational risks of bladder cancer in the United States: I. White men. J Natl Cancer Inst 81(19):1472–1480PubMed
107.
Sorahan T, Hamilton L, Jackson JR (2000) A further cohort study of workers employed at a factory manufacturing chemicals for the rubber industry, with special reference to the chemicals 2-mercaptobenzothiazole (MBT), aniline, phenyl-beta-naphthylamine and o-toluidine. Occup Environ Med 57(2):106–115PubMed
108.
Leppert JT, Shvarts O, Kawaoka K, Lieberman R, Belldegrun AS, Pantuck AJ (2006) Prevention of bladder cancer: a review. Eur Urol 49(2):226–234PubMed
109.
Rafnsson V, Sulem P (2003) Cancer incidence among marine engineers, a population-based study (Iceland). Cancer Causes Control 14(1):29–35PubMed
110.
Mastrangelo G, Fedeli U, Fadda E, Milan G, Lange JH (2002) Epidemiologic evidence of cancer risk in textile industry workers: a review and update. Toxicol Ind Health 18(4):171–181PubMed
111.
Kogevinas M, Sala M, Boffetta P, Kazerouni N, Kromhout H, Hoar-Zahm S (1998) Cancer risk in the rubber industry: a review of the recent epidemiological evidence. Occup Environ Med 55(1):1–12PubMed
112.
Kellen E, Zeegers M, Paulussen A, Vlietinck R, Vlem EV, Veulemans H, Buntinx F (2006) Does occupational exposure to PAHs, diesel, aromatic amines interact with smoking and metabolic genetic polymorphisms to increase the risk on bladder cancer? The Belgian case control study on bladder cancer risk. Cancer Lett
113.
Kogevinas M, A. t Mannetje, Cordier S, Ranft U, Gonzalez CA, Vineis P, Chang-Claude J, Lynge E, Wahrendorf J, Tzonou A, Jockel KH, Serra C, Porru S, Hours M, Greiser E, and Boffetta P (2003) Occupation and bladder cancer among men in Western Europe. Cancer Causes Control 14(10):907–914
114.
Boffetta P, Silverman DT (2001) A meta-analysis of bladder cancer and diesel exhaust exposure. Epidemiology 12(1):125–130PubMed
115.
Gun RT, Pratt NL, Griffith EC, Adams GG, Bisby JA, Robinson KL (2004) Update of a prospective study of mortality and cancer incidence in the Australian petroleum industry. Occup Environ Med 61(2):150–156PubMed
116.
Lewis RJ, Schnatter AR, Drummond I, Murray N, Thompson FS, Katz AM, Jorgensen G, Nicolich MJ, Dahlman D, Theriault G (2003) Mortality and cancer morbidity in a cohort of Canadian petroleum workers. Occup Environ Med 60(12):918–928PubMed
117.
Romundstad P, Haldorsen T, Andersen A (2000) Cancer incidence and cause specific mortality among workers in two Norwegian aluminum reduction plants. Am J Ind Med 37(2):175–183PubMed
118.
Grandjean P, Olsen JH (2004) Extended follow-up of cancer incidence in fluoride-exposed workers. J Natl Cancer Inst 96(10):802–803PubMed
119.
Perera FP (1997) Environment and cancer: who are susceptible? Science 278(5340):1068–1073PubMed
120.
Vineis P, Landi MT, Caporaso N (1992) Metabolic polymorphisms and the cancer risk: the evaluation of epidemiological studies. Med Lav 83(6):557–575PubMed
121.
Silverman DT, Hartge P, Morrison AS, Devesa SS (1992) Epidemiology of bladder cancer. Hematol Oncol Clin North Am 6(1):1–30PubMed
122.
Grossman HB, Schmitz-Drager B, Fradet Y, Tribukait B (2000) Use of markers in defining urothelial premalignant, malignant conditions. Scand J Urol Nephrol Suppl, (205):94–104
123.
Marcus PM, Hayes RB, Vineis P, Garcia-Closas M, Caporaso NE, Autrup H, Branch RA, Brockmoller J, Ishizaki T, Karakaya AE, Ladero JM, Mommsen S, Okkels H, Romkes M, Roots I, Rothman N (2000) Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: a case-series meta-analysis of a gene-environment interaction. Cancer Epidemiol Biomarkers Prev 9(5):461–467PubMed
124.
Curigliano G, Zhang YJ, Wang LY, Flamini G, Alcini A, Ratto C, Giustacchini M, Alcini E, Cittadini A, Santella RM (1996) Immunohistochemical quantitation of 4-aminobiphenyl-DNA adducts and p53 nuclear overexpression in T1 bladder cancer of smokers and nonsmokers. Carcinogenesis 17(5):911–916PubMed
125.
Brennan P, Bogillot O, Greiser E, Chang-Claude J, Wahrendorf J, Cordier S, Jockel KH, Lopez-Abente G, Tzonou A, Vineis P, Donato F, Hours M, Serra C, Bolm-Audorff U, Schill W, Kogevinas M, Boffetta P (2001) The contribution of cigarette smoking to bladder cancer in women (pooled European data). Cancer Causes Control 12(5):411–417PubMed
126.
Zeegers MP, Kellen E, Buntinx F, van den Brandt PA (2004) The association between smoking, beverage consumption, diet and bladder cancer: a systematic literature review. World J Urol 21(6):392–401PubMed
127.
Zeegers MP, Tan FE, Dorant E, van Den Brandt PA (2000) The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer 89(3):630–639PubMed
128.
Leistikow BSW (2001) California’s reductions in smoking and bladder cancer incidence:a success story. J Urol 165
129.
Thompson IM, Peek M, Rodriguez FR (1987) The impact of cigarette smoking on stage, grade and number of recurrences of transitional cell carcinoma of the bladder. J Urol 137(3):401–403PubMed
130.
Raitanen MP, Nieminen P, Tammela TL (1995) Impact of tumour grade, stage, number and size, and smoking and sex, on survival in patients with transitional cell carcinoma of the bladder. Br J Urol 76(4):470–474PubMedCrossRef
131.
Burch JD, Rohan TE, Howe GR, Risch HA, Hill GB, Steele R, Miller AB (1989) Risk of bladder cancer by source and type of tobacco exposure: a case-control study. Int J Cancer 44(4):622–628PubMed
132.
Hartge P, Hoover R, Kantor A (1985) Bladder cancer risk and pipes, cigars, and smokeless tobacco. Cancer 55(4):901–906PubMed
133.
Steineck G, Norell SE, Feychting M (1988) Diet, tobacco and urothelial cancer. A 14-year follow-up of 16,477 subjects. Acta Oncol 27(4):323–327PubMed
134.
Dolin P (1991) An epidemiological rereview of tobacco use and bladder cancer. J Smoking related Dis 2:129–143
135.
Johansson SL, Cohen SM (1997) Epidemiology and etiology of bladder cancer. Semin Surg Oncol 13(5):291–298PubMed
136.
Sandler DP, Everson RB, Wilcox AJ (1985) Passive smoking in adulthood and cancer risk. Am J Epidemiol 121(1):37–48PubMed
137.
Bos RP, Theuws JL, Henderson PT (1983) Excretion of mutagens in human urine after passive smoking. Cancer Lett 19(1):85–90PubMed
138.
Sandler DP, Wilcox AJ, Everson RB (1985) Cumalitive effects of lifetime passive smoking on cancer risk. Lancet 1:312–315PubMed
139.
Tseng WP (1989) Blackfoot disease in Taiwan: a 30-year follow-up study. Angiology 40(6):547–558PubMed
140.
Yang CY, Chiu HF, Chang CC, Ho SC, Wu TN (2005) Bladder cancer mortality reduction after installation of a tap-water supply system in an arsenious-endemic area in southwestern Taiwan. Environ Res 98(1):127–132PubMed
141.
Agency for Toxic Substances and Disease Registry (1989) US Public Health Service. Toxicological profile for arsenic. Publication no. ATSDR/TP-88/02. US Public Health Service, Washington DC
142.
World Health Organization (1981) Arsenic. Environmental health criteria. World Health Organization, Geneva, pp 33–49
143.
Chiou HY, Chiou ST, Hsu YH, Chou YL, Tseng CH, Wei ML, Chen CJ (2001) Incidence of transitional cell carcinoma and arsenic in drinking water: a follow-up study of 8,102 residents in an arseniasis-endemic area in northeastern Taiwan. Am J Epidemiol 153(5):411–418PubMed
144.
Chen CJ, Chen CW, Wu MM, Kuo TL (1992) Cancer potential in liver, lung, bladder and kidney due to ingested inorganic arsenic in drinking water. Br J Cancer 66(5):888–892PubMed
145.
Chen CJ, Chuang YC, Lin TM, Wu HY (1985) Malignant neoplasms among residents of a blackfoot disease-endemic area in Taiwan: high-arsenic artesian well water and cancers. Cancer Res 45(11 Pt 2):5895–5899PubMed
146.
Chen CJ, Kuo TL, Wu MM (1988) Arsenic and cancers. Lancet 1(8582):414–415PubMed
147.
Chen CJ, Wang CJ (1990) Ecological correlation between arsenic level in well water and age-adjusted mortality from malignant neoplasms. Cancer Res 50(17):5470–5474PubMed
148.
Chen CJ, Wu MM, Lee SS, Wang JD, Cheng SH, Wu HY (1988) Atherogenicity and carcinogenicity of high-arsenic artesian well water. Multiple risk factors and related malignant neoplasms of blackfoot disease. Arteriosclerosis 8(5):452–460PubMed
149.
Tseng WP (1977) Effects and dose–response relationships of skin cancer and blackfoot disease with arsenic. Environ Health Perspect 19:109–119PubMed
150.
Moore, L.e.a (1999) Epidemiologic and molecular epidemiologic methods to assess the mechanistic role of arsenic in bladder cancer evaluation. Epidemiology
151.
Hsu YH, Li SY, Chiou HY, Yeh PM, Liou JC, Hsueh YM, Chang SH, Chen CJ (1997) Spontaneous and induced sister chromatid exchanges and delayed cell proliferation in peripheral lymphocytes of Bowen’s disease patients and matched controls of arseniasis-hyperendemic villages in Taiwan. Mutat Res 386(3):241–251PubMed
152.
Chiou HY, Hsueh YM, Hsieh LL, Hsu LI, Hsu YH, Hsieh FI, Wei ML, Chen HC, Yang HT, Leu LC, Chu TH, Chen-Wu C, Yang MH, Chen CJ (1997) Arsenic methylation capacity, body retention, and null genotypes of glutathione S-transferase M1 and T1 among current arsenic-exposed residents in Taiwan. Mutat Res 386(3):197–207PubMed
153.
Shibata A, Ohneseit PF, Tsai YC, Spruck CH 3rd, Nichols PW, Chiang HS, Lai MK, Jones PA (1994) Mutational spectrum in the p53 gene in bladder tumors from the endemic area of black foot disease in Taiwan. Carcinogenesis 15(6):1085–1087PubMed
154.
Environmental Protection Agency (2001) National Primary Drinking Water Regulations: arsenic and clarifications to compliance and new source contaminants monitoring; final rule. Federal Regulation 66 (no. 14). Environmental Protection Agency, Washington, DC, p 6976–7066
155.
Angervall L, Bentsson U, Zetterland CG, Zsigmond M (1969) Renal pelvis carcinoma in a Swedish district with abuse of a phenacetin-containing drug. Br J Urol 41:401–405
156.
Jensen OM, Knudsen JB, Tomasson H, Sörensen BL (1989) The Copenhagen case-control study of renal pelvis and ureter cancer: Role of analgesics. Int J Cancer 44:965–968
157.
Linet MS, Chow WH, McLaughlin JK et al (1995) Analgesics and cancers of renal pelvis and ureter. Int J Cancer 62:15–18
158.
McCredie M, Stewart J, Day NE (1993) Different roles for phenacetin and paracetamol in cancer of the kidney and renal pelvis. Int J Cancer 53:245–249
159.
McCredie M, Stewart J, Ford JM, McLennan RA (1983) Phenacetin-containing analgesics and cancer of the bladder or renal pelvis in women. Br J Urology 55:220–224
160.
Mihatsch MJ, Knüsli C (1982) Phenacetin abuse and malignant tumors. Klin Wochenschr 60:1339–1349
161.
Piper JM, Tonascia J, Matanoski GM (1985) Heavy phenacetin use and bladder cancer in women aged 20 to 49 years. N Engl J Med 313:292–305
162.
McLaughlin JK, Blot WJ, Devesa SS, Fraumeni, JF (1996) Renal cancer. In: Schottenfeld D, Fraumeni JF (eds) Cancer epidemiology and prevention, 2nd edn. Oxford University Press, New York, pp 1142–1155
163.
Silverman DT, Morrison AS, Devesa SS (1996) Bladder cancer. In: Schottenfeld D, Fraumeni JF (eds) Cancer epidemiology and prevention, 2nd edn. Oxford University Press, New York, pp 1156–1179
164.
Pommer W, Bronder E, Klimpel A, Helmert U, Greiser E, Molzahn M (1999) Urothelial cancer at different tumour sites: role of smoking and habitual intake of analgesics and laxatives. Results of the Berlin Urothelial Cancer Study. Nephrol Dial Transplant 14:2892–2897PubMed
165.
Vanherweghem JL, Depierreux M, Tielemans C, Abramowicz D, Dratwa M, Jadoul M, Richard C, Vandervelde D, Verbeelen D, Vanhaelen-Fastre R et al (1993) Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 341(8842):387–391PubMed
166.
Mengs U, Lang W, Poch J-A (1982) The carcinogenic action of aristolochic acid in rats. Arch Toxicol 51:107–119
167.
Pezzuto JM, Swanson SM, Mar W, Che C, Cordell GA, Fong HHS (1988) Evaluation of the mutagenic and cytostatic potential of aristolochic acid (3,4-methylenedioxy-8-methoxy-10-nitrophenanthrene-1-carboxylic acid) and several of its derivatives. Mutat Res 206:447–454
168.
Schmeiser HH, Pool BL, Wiessler M (1986) Identification and mutagenicity of metabolites of aristolochic acid formed by rat liver. Carcinogenesis 7(1):59–63PubMed
169.
Schmeiser HH, BC, Wiessler M, van Ypersele de Strihou C, Cosyns JP (1996) Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy. Cancer Resx 56:2025–2028
170.
Nortier JL, Martinez MC, Schmeiser HH, Arlt VM, Bieler CA, Petein M, Depierreux MF, De Pauw L, Abramowicz D, Vereerstraeten P, Vanherweghem JL (2000) Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 342(23):1686–1692PubMed
171.
Cosyns JP, Jadoul M, Squifflet JP, Wese FX, van Ypersele de Strihou C (1999) Urothelial lesions in Chinese-herb nephropathy. Am J Kidney Dis 33:1011–1017
172.
Lord GM, Tagore R, Cook T, Gower P, Pusey CD (1999) Nephropathy caused by Chinese herbs in the UK. Lancet 354(9177):481–482PubMed
173.
Pena JM, Borras M, Ramos J, Montoliu J (1996) Rapidly progressive interstitial renal fibrosis due to a chronic intake of a herb (Aristolochia pistolochia) infusion. Nephrol Dial Transplant 11(7):1359–1360PubMed
174.
Pourrat J, Montastruc JL, Lacombe JL, Cisterne JM, Rascol O, Dumazer P (1994) Nephropathy associated with Chinese herbal drugs. 2 cases. Presse Med 23(36):1669PubMed
175.
Tanaka A, Shinkai S, Kasuno K, Maeda K, Murata M, Seta K, Okuda J, Sugawara A, Yoshida T, Nishida R, Kuwahara T (1997) Chinese herbs nephropathy in the Kansai area: a warning report. Nippon Jinzo Gakkai Shi 39(4):438–440PubMed
176.
Mostafa MH, Sheweita SA, O’Connor PJ (1999) Relationship between schistosomiasis and bladder cancer. Clin Microbiol Rev 12(1):97–111PubMed
177.
Cheever AW (1978) Schistosomiasis and neoplasia. J Natl Cancer Inst 61(1):13–18PubMed
178.
El-Bolkainy MN, Mokhtar NM, Ghoneim MA, Hussein MH (1981) The impact of schistosomiasis on the pathology of bladder carcinoma. Cancer 48(12):2643–2648PubMed
179.
Schwartz DA (1981) Helminths in the induction of cancer. II. Schistosoma haematobium and bladder cancer. Trop Geogr Med 33:1–7PubMed
180.
Sherif M, El-Mawla NG, El-Bolkainy N, Badawi S, Awwad H (1975) Clinical staging of malignant lymphoma in patients suspected to have hepato-splenic schistosomiasis. J Trop Med Hyg 78(3):67–70PubMed
181.
Badawi AF, Mostafa MH, Aboul-Azm T, Haboubi NY, O’Connor PJ, Cooper DP (1992) Promutagenic methylation damage in bladder DNA from patients with bladder cancer associated with schistosomiasis and from normal individuals. Carcinogenesis 13(5):877–881PubMed
182.
Chen MG, Mott KE (1989) Progress in the assessment of morbidity due to Shistosoma haematobium infections: a review of the recent literature. Trop Dis Bull. 48:2643–2648
183.
World Health Organization (1994) Evaluation of carcinogenic risk to humans. Schistosomes, liver flukes and Helicobacter pylori. IARC Monogr 61:45–119
184.
World Health Organization (1985) World Health Organization technical report series, vol 728. The control of schistosomiasis. Report of a WHO Expert Committee. World Health Organization, Geneva, Switzerland
185.
Ibrahim AS (1986) Site distribution of cancer in Egypt: twelve years experience (1970–1981), 45–50. In: Khogali M, Omar YT, Gjorgov A, Ismail AS (eds) Cancer prevention in developing countries. Pergamon Press, Oxford, United Kingdom
186.
Kahan E, Ibrahim AS, El Najjar K, Ron E, Al-Agha H, Polliak A, El-Bolkasiny NM (1997) Cancer patterns in the Middle East. Special report from the Middle East Cancer Society. Act Oncol 36:631–636CrossRef
187.
Koraitim NM, Metwalli NE, Atta MA, El-Sadr AA (1995) Changing age incidence and pathological types of Schistosoma-associated bladder carcinoma. J Urol 154:1714–1716PubMed
188.
Marletta MA (1988) Mammalian synthesis of nitrite, nitrate, nitric oxide and N-nitosating agents. Chem Res Toxicol 1:249–257
189.
O’Brien PJ (1988) Radical formation during the peroxidase-catalised metabolism of carcinogens and xenobiotics. The reactivity of these radicals with GSH, DNA and unsaturated fatty lipid. Free Radical Biol Med 4:216–226
190.
Mostafa MH, Helmi S, Badawi AF, Tricker AR, Spiegelhalder B, Preussmann R (1994) Nitrate, nitrite and volatile N-nitroso compounds in the urine of Schistosoma haematobium and Schistosoma mansoni infected patients. Carcinogenesis 15(4):619–625PubMed
191.
Hicks RM, Ismail MM, Walters CL, Beecham PT, Rabie MT, El-Alamy MA (1982) Association of bacteriuria and urinary nitrosamine formation with Schistosomiasis haematobium infection in the Qalyub area of Egypt. Trans R Soc Trop Med Hyg 76:519–527PubMed
192.
Habuchi T, Takahashi R, Yamada H, Kakehi O, Ourga K, Hamazaki S, Toguchida J, Ishizaki K, Yoshida O (1993) Influence of cigarette smoking and schistosomiasis on p53 gene mutation in urothelial cancer. Cancer Res 53:3795–3799PubMed
193.
Nurse P (1997) Regulation of the eukaryotic cell cycle. Eur J Cancer 33:1002–1004PubMed
194.
Oyasu R, Hopp ML (1974) The etiology of cancer of the bladder. Surg Gynecol Obstet 138(1):97–108PubMed
195.
Melicow MM (1974) Tumors of the bladder: a multifaceted problem. J Urol 112(4):467–478PubMed
196.
Vena JE, Graham S, Freudenheim J, Marshall J, Zielezny M, Swanson M, Sufrin G (1993) Drinking water, fluid intake, and bladder cancer in western New York. Arch Environ Health 48(3):191–198PubMedCrossRef
197.
Kunze E Chang-Claude J, Frentzel-Beyme R (1992) Life style and occupational risk factors for bladder cancer in Germany. A case-control study. Cancer 69(7):1776–1790
198.
Claude J, Kunze E, Frentzel-Beyme R, Paczkowski K, Schneider J, Schubert H (1986) Life-style and occupational risk factors in cancer of the lower urinary tract. Am J Epidemiol 124(4):578–589PubMed
199.
Bianchi GD, Cerhan JR, Parker AS, Putnam SD, See WA, Lynch CF, Cantor KP (2000) Tea consumption and risk of bladder and kidney cancers in a population-based case-control study. Am J Epidemiol 151(4):377–383PubMed
200.
Slattery ML, West DW, Robison LM (1988) Fluid intake and bladder cancer in Utah. Int J Cancer 42(1):17–22PubMed
201.
Risch HA, Burch JD, Miller AB, Hill GB, Steele R, Howe GR (1988) Dietary factors and the incidence of cancer of the urinary bladder. Am J Epidemiol 127(6):1179–1191PubMed
202.
Geoffroy-Perez B, Cordier S (2001) Fluid consumption and the risk of bladder cancer: results of a multicenter case-control study. Int J Cancer 93(6):880–887PubMed
203.
Michaud DS, Spiegelman D, Clinton SK, Rimm EB, Curhan GC, Willett WC, Giovannucci EL (1999) Fluid intake and the risk of bladder cancer in men. N Engl J Med 340(18):1390–1397PubMed
204.
Lopez-Abente G, Escolar A (2001) Tobacco consumption and bladder cancer in non-coffee drinkers. J Epidemiol Comm Health 55(1):68–70
205.
Glade MJ, Food, nutrition, and the prevention of cancer:a global perspective. Nutrition, 1997 15(6):523–526
206.
Michaud DS, Spiegelman D, Clinton SK, Rimm EB, Willett WC, Giovannucci EL (1999) Fruit and vegetable intake and incidence of bladder cancer in a male prospective cohort. J Natl Cancer Inst 91(7):605–613PubMed
207.
Nagano J, Kono S, Preston DL, Moriwaki H, Sharp GB, Koyama K, Mabuchi K (2000) Bladder-cancer incidence in relation to vegetable and fruit consumption: a prospective study of atomic-bomb survivors. Int J Cancer 86(1):132–138PubMed
208.
Michaud DS, Pietinen P, Taylor PR, Virtanen M, Virtamo J, Albanes D (2002) Intakes of fruits and vegetables, carotenoids and vitamins A, E, C in relation to the risk of bladder cancer in the ATBC cohort study. Br J Cancer 87(9): 960–965PubMed
209.
Messina M, Barnes S (1991) The role of soy products in reducing risk of cancer. J Natl Cancer Inst 83(8):541–546PubMed
210.
Yan L, Spitznagel EL (2005) Meta-analysis of soy food and risk of prostate cancer in men. Int J Cancer 117(4):667–669PubMed
211.
Zhou JR, Mukherjee P, Gugger ET, Tanaka T, Blackburn GL, Clinton SK (1998) Inhibition of murine bladder tumorigenesis by soy isoflavones via alterations in the cell cycle, apoptosis, and angiogenesis. Cancer Res 58(22):5231–5238PubMed
212.
Su SJ, Yeh TM, Lei HY, Chow NH (2000) The potential of soybean foods as a chemoprevention approach for human urinary tract cancer. Clin Cancer Res 6(1):230–236PubMed
213.
Sun CL, Yuan JM, Wang XL, Gao YT, Ross RK, Yu MC (2004) Dietary soy and increased risk of bladder cancer: a prospective cohort study of men in Shanghai, China. Int J Cancer 112(2):319–323PubMed
214.
Garland M, Morris JS, Stampfer MJ, Colditz GA, Spate VL, Baskett CK, Rosner B, Speizer FE, Willett WC, Hunter DJ (1995) Prospective study of toenail selenium levels and cancer among women. J Natl Cancer Inst 87(7):497–505PubMed
215.
Helzlsouer KJ, Comstock GW, Morris JS (1989) Selenium, lycopene, alpha-tocopherol, beta-carotene, retinol, and subsequent bladder cancer. Cancer Res 49(21):6144–6148PubMed
216.
Sigounas G, Hooker J, Anagnostou A, Steiner M (1997) S-allylmercaptocysteine inhibits cell proliferation and reduces the viability of erythroleukemia, breast, and prostate cancer cell lines. Nutr Cancer 27(2):186–191PubMed
217.
Pinto JT, Qiao C, Xing J, Suffoletto BP, Schubert KB, Rivlin RS, Huryk RF, Bacich DJ, Heston WD (2000) Alterations of prostate biomarker expression and testosterone utilization in human LNCaP prostatic carcinoma cells by garlic-derived S-allylmercaptocysteine. Prostate 45(4):304–314PubMed
218.
Lamm DL, Riggs DR (2001) Enhanced immunocompetence by garlic: role in bladder cancer and other malignancies. J Nutr 131(3s):1067S–1070SPubMed
219.
Key TJ, Silcocks PB, Davey GK, Appleby PN, Bishop DT (1997) A case-control study of diet and prostate cancer. Br J Cancer 76(5):678–687PubMed
220.
Dorant E, van den Brandt PA, Goldbohm RA, Sturmans F (1996) Consumption of onions and a reduced risk of stomach carcinoma. Gastroenterology 110(1):12–20PubMed
221.
Dorant E, van den Brandt PA, Goldbohm RA (1996) A prospective cohort study on the relationship between onion and leek consumption, garlic supplement use and the risk of colorectal carcinoma in The Netherlands. Carcinogenesis 17(3):477–484PubMed
222.
Dorant E, van den Brandt PA, Goldbohm RA (1994) A prospective cohort study on Allium vegetable consumption, garlic supplement use, and the risk of lung carcinoma in The Netherlands. Cancer Res 54(23):6148–6153PubMed
223.
Dorant E, van den Brandt PA, Goldbohm RA (1995) Allium vegetable consumption, garlic supplement intake, and female breast carcinoma incidence. Breast Cancer Res Treat 33(2):163–170PubMed
224.
Riboli E, Gonzalez CA, Lopez-Abente G, Errezola M, Izarzugaza I, Escolar A, Nebot M, Hemon B, Agudo A (1991) Diet and bladder cancer in Spain: a multi-centre case-control study. Int J Cancer 49(2):214–219PubMed
225.
Steinmaus CM, Nunez S, Smith AH (2000) Diet and bladder cancer: a meta-analysis of six dietary variables. Am J Epidemiol 151(7):693–702PubMed
226.
Radosavljevic V, Jankovic S, Marinkovic J, Dokic M (2005) Diet and bladder cancer: a case-control study. Int Urol Nephrol 37(2):283–289PubMed
227.
Steineck G, Hagman U, Gerhardsson M, Norell SE (1990) Vitamin A supplements, fried foods, fat and urothelial cancer. A case-referent study in Stockholm in 1985–87. Int J Cancer 45(6):1006–1011PubMed
228.
Wolbach S (1925) Tissue changes following deprivation of fat-soluble A vitamin. J Exp Med
229.
Cohen SM, Wittenberg JF, Bryan GT (1976) Effect of avitaminosis A and hypervitaminosis A on urinary bladder carcinogenicity of N-(4-(5-Nitro-2-furyl)-2-thiazolyl)formamide. Cancer Res 36(7 PT 1):2334–2339
230.
Sporn MB, Squire RA, Brown CC, Smith JM, Wenk ML, Springer S (1977) 13-cis-retinoic acid: inhibition of bladder carcinogenesis in the rat. Science 195(4277):487–489PubMed
231.
Kakizoe T (2003) Chemoprevention of cancer–focusing on clinical trials. Jpn J Clin Oncol 33(9):421–442PubMed
232.
Mettlin C, Graham S (1979) Dietary risk factors in human bladder cancer. Am J Epidemiol 110(3):255–263PubMed
233.
Eichholzer M, Stahelin HB, Gey KF, Ludin E, Bernasconi F (1996) Prediction of male cancer mortality by plasma levels of interacting vitamins: 17-year follow-up of the prospective Basel study. Int J Cancer 66(2):145–150PubMed
234.
Prout GR Jr, Barton BA (1992) 13-cis-retinoic acid in chemoprevention of superficial bladder cancer. The National Bladder Cancer Group. J Cell Biochem Suppl 16I:148–152PubMed
235.
Clifford JL, Sabichi AL, Zou C, Yang X, Steele VE, Kelloff GJ, Lotan R, Lippman SM (2001) Effects of novel phenylretinamides on cell growth and apoptosis in bladder cancer. Cancer Epidemiol Biomarkers Prev 10(4):391–395PubMed
236.
Studer UE, Jenzer S, Biedermann C, Chollet D, Kraft R, von Toggenburg H, Vonbank F (1995) Adjuvant treatment with a vitamin A analogue (etretinate) after transurethral resection of superficial bladder tumors. Final analysis of a prospective, randomized multicenter trial in Switzerland. Eur Urol 28(4):284–290PubMed
237.
Seth P Lerner*, A.L.S, H Barton Grossman, Houston, TX; David F Penson, Los Angeles, CA; Colin P N Dinney, Houston, TX; George Hemstreet, III, Omaha, NE; Edward N Atkinson, Nancy Caraway, Ruth Katz, Scott M Lippman, Houston, TX (2005) Results of a randomised chemoprevention trial with fenretinide in non-muscle invasive bladder cancer
238.
Newling DW, Robinson MR, Smith PH, Byar D, Lockwood R, Stevens I, De Pauw M, Sylvester R (1995) Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group. EORTC Genito-Urinary Tract Cancer Cooperative Group. Eur Urol 27(2):110–116PubMed
239.
Brown RR, Price JM, Satter EJ, Wear JB (1960) The metabolism of tryptophan in patients with bladder cancer. Acta Unio Int Contra Cancrum 16:299–303PubMed
240.
Byar D, Blackard C (1977) Comparisons of placebo, pyridoxine, and topical thiotepa in preventing recurrence of stage I bladder cancer. Urology 10(6):556–561PubMed
241.
Schlegel JU (1975) Proposed uses of ascorbic acid in prevention of bladder carcinoma. Ann N Y Acad Sci 258: 432–437PubMed
242.
Birt DF (1986) Update on the effects of vitamins A, C, and E and selenium on carcinogenesis. Proc Soc Exp Biol Med 183(3):311–320PubMed
243.
Shibata A, Paganini-Hill A, Ross RK, Henderson BE (1992) Intake of vegetables, fruits, beta-carotene, vitamin C and vitamin supplements and cancer incidence among the elderly: a prospective study. Br J Cancer 66(4):673–679PubMed
244.
Nomura AM, Kolonel LN, Hankin JH, Yoshizawa CN (1991) Dietary factors in cancer of the lower urinary tract. Int J Cancer 48(2):199–205PubMed
245.
Bruemmer B, White E, Vaughan TL, Cheney CL (1996) Nutrient intake in relation to bladder cancer among middle-aged men and women. Am J Epidemiol 144(5):485–495PubMed
246.
Michaud DS, Spiegelman D, Clinton SK, Rimm EB, Willett WC, Giovannucci E (2000) Prospective study of dietary supplements, macronutrients, micronutrients, and risk of bladder cancer in US men. Am J Epidemiol 152(12):1145–1153PubMed
247.
Mirvish SS (1986) Effects of vitamins C and E on N-nitroso compound formation, carcinogenesis, and cancer. Cancer 58(8 Suppl):1842–1850PubMed
248.
Fukushima S, Imaida K, Sakata T, Okamura T, Shibata M, Ito N (1983) Promoting effects of sodium L-ascorbate on two-stage urinary bladder carcinogenesis in rats. Cancer Res 43(9):4454–4457PubMed
249.
Taylor EN, Stampfer MJ, Curhan GC (2004) Dietary factors and the risk of incident kidney stones in men: new insights after 14 years of follow-up. J Am Soc Nephrol 15(12):3225–3232PubMed
250.
Chai W, Liebman M, Kynast-Gales S, Massey L (2004) Oxalate absorption and endogenous oxalate synthesis from ascorbate in calcium oxalate stone formers and non-stone formers. Am J Kidney Dis 44(6):1060–1069PubMed
251.
Wroblewski K (2005) Can the administration of large doses of vitamin C have a harmful effect?. Pol Merkuriusz Lek 19(112):600–603
252.
Beisel WR, Edelman R, Nauss K, Suskind RM (1981) Single-nutrient effects on immunologic functions. Report of a workshop sponsored by the Department of Food and Nutrition and its nutrition advisory group of the American Medical Association. Jama 245(1):53–58PubMed
253.
Jacobs EJ, Henion AK, Briggs PJ, Connell CJ, McCullough ML, Jonas CR, Rodriguez C, Calle EE, Thun MJ (2002) Vitamin C and vitamin E supplement use and bladder cancer mortality in a large cohort of US men and women. Am J Epidemiol 156(11):1002–1010PubMed
254.
The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group (1994) The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 330 (15):1029–1035
255.
Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E (2005) Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 142(1):37–46
256.
Lamm DL, Riggs DR, Shriver JS, vanGilder PF, Rach JF, DeHaven JI (1994) Megadose vitamins in bladder cancer: a double-blind clinical trial. J Urol 151(1):21–26PubMed
257.
Messing EM, Hanson P, Reznikoff CA (1988) Normal and malignant human urothelium: in vitro response to blockade of polyamine synthesis and interconversion. Cancer Res 48(2):357–361 PM:3275496
258.
Homma Y, Ozono S, Numata I, Seidenfeld J, Oyasu R (1985) Inhibition of carcinogenesis by alpha-difluoromethylornithine in heterotopically transplanted rat urinary bladders. Cancer Res 45(2):648–652PubMed
259.
Loprinzi CL, Messing EM, O’Fallon JR, Poon MA, Love RR, Quella SK, Trump DL, Morton RF, Novotny P (1996) Toxicity evaluation of difluoromethylornithine: doses for chemoprevention trials. Cancer Epidemiol Biomarkers Prev 5(5):371 PM:9162303
260.
Messing EM, Love RR, Tutsch KD, Verma AK, Douglas J, Pomplun M, Simsiman R, Wilding G (1999) Low-dose difluoromethylornithine and polyamine levels in human prostate tissue. J Natl Cancer Inst 91(16):1416–1417PubMed
261.
Messing E, Kim KM, Sharkey F, Schultz M, Parnes H, Kim D, Saltzstein D, Wilding G (2006) Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer. J Urol 176(2):500–504PubMed
262.
Rao KV, Detrisac CJ, Steele VE, Hawk ET, Kelloff GJ, McCormick DL (1996) Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder. Carcinogenesis 17(7):1435–1438PubMed
263.
Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr (1993) Aspirin use and risk of fatal cancer. Cancer Res 53(6):1322–1327PubMed
264.
Castelao JE, Yuan JM, Gago-Dominguez M, Yu MC, Ross RK (2000) Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer 82(7):1364–1369PubMed
265.
Ristimaki A, Narko K, Hla T (1996) Down-regulation of cytokine-induced cyclo-oxygenase-2 transcript isoforms by dexamethasone: evidence for post-transcriptional regulation. Biochem J 318(Pt 1):325–331PubMed
266.
Watson AJ (1998) Chemopreventive effects of NSAIDs against colorectal cancer: regulation of apoptosis and mitosis by COX-1 and COX-2. Histol Histopathol 13(2):591–597PubMed
267.
Kitayama W, Denda A, Okajima E, Tsujiuchi T, Konishi Y (1999) Increased expression of cyclooxygenase-2 protein in rat urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl) nitrosamine. Carcinogenesis 20(12):2305–2310PubMed
268.
Khan KN, Knapp DW, Denicola DB, Harris RK (2000) Expression of cyclooxygenase-2 in transitional cell carcinoma of the urinary bladder in dogs. Am J Vet Res 61(5):478–481PubMed
269.
Grubbs CJ, Lubet RA, Koki AT, Leahy KM, Masferrer JL, Steele VE, Kelloff GJ, Hill DL, Seibert K (2000) Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res 60(20):5599–5602PubMed
270.
Gee J, Lee IL, Jendiroba D, Fischer SM, Grossman HB, Sabichi AL (2006) Selective cyclooxygenase-2 inhibitors inhibit growth and induce apoptosis of bladder cancer. Oncol Rep 15(2):471–477PubMed
271.
Shirahama T (2000) Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder. Clin Cancer Res 6(6):2424–2430PubMed
272.
Ristimaki A, Nieminen O, Saukkonen K, Hotakainen K, Nordling S, Haglund C (2001) Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder. Am J Pathol 158(3):849–853PubMed
273.
Mohammed SI, Knapp DW, Bostwick DG, Foster RS, Khan KN, Masferrer JL, Woerner BM, Snyder PW, Koki AT (1999) Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res 59(22):5647–5650PubMed
274.
Komhoff M, Guan Y, Shappell HW, Davis L, Jack G, Shyr Y, Koch MO, Shappell SB, Breyer MD (2000) Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas. Am J Pathol 157(1):29–35PubMed
275.
Shariat SF, Kim JH, Ayala GE, Kho K, Wheeler TM, Lerner SP (2003) Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder. J Urol 169(3):938–942PubMed
276.
Lerner SP (2005) Bladder cancer clinical trials. Urol Oncol 23(4):275–279PubMed
277.
Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352(11):1092–1102PubMed
278.
Zaveri NT (2006) Green tea and its polyphenolic catechins: medicinal uses in cancer and noncancer applications. Life Sci 78(18):2073–2080PubMed
279.
Bushman JL (1998) Green tea and cancer in humans: a review of the literature. Nutr Cancer 31(3):151–159PubMedCrossRef
280.
Higdon JV, Frei B (2003) Tea catechins and polyphenols: health effects, metabolism, and antioxidant functions. Crit Rev Food Sci Nutr 43(1):89–143PubMed
281.
Komori A, Yatsunami J, Okabe S, Abe S, Hara K, Suganuma M, Kim SJ, Fujiki H (1993) Anticarcinogenic activity of green tea polyphenols. Jpn J Clin Oncol 23(3):186–190PubMed
282.
Kemberling JK, Hampton JA, Keck RW, Gomez MA, Selman SH (2003) Inhibition of bladder tumor growth by the green tea derivative epigallocatechin-3-gallate. J Urol 170(3):773–776PubMed
283.
Sato D, Matsushima M (2003) Preventive effects of urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl)-nitrosamine in rat by green tea leaves. Int J Urol 10(3):160–166PubMed
284.
Messing EM, Reznikoff CA (1987) Normal and malignant human urothelium: in vitro effects of epidermal growth factor. Cancer Res 47(9):2230–2235PubMed
285.
Messing EM, Hanson P, Ulrich P, Erturk E (1987) Epidermal growth factor–interactions with normal and malignant urothelium: in vivo and in situ studies. J Urol 138(5):1329–1335PubMed
286.
Lu QY, Jin YS, Pantuck A, Zhang ZF, Heber D, Belldegrun A, Brooks M, Figlin R, Rao J (2005) Green tea extract modulates actin remodeling via Rho activity in an in vitro multistep carcinogenic model. Clin Cancer Res 11(4):1675–1683PubMed
287.
Steele VE, Bagheri D, Balentine DA, Boone CW, Mehta R, Morse MA, Sharma S, Sigman CC, Stoner GD, Wargovich MJ, Weisburger JH, Zhu S, Kelloff GJ (1999) Preclinical efficacy studies of green and black tea extracts. Proc Soc Exp Biol Med 220(4):210–212PubMed
288.
Hemstreet GP III, Rao JY, Hurst RE, Bonner RB, Jones PL, Vaidya AM, Fradet Y, Moon RC, Kelloff GJ (1992) Intermediate endpoint biomarkers for chemoprevention. J Cell Biochem Suppl 16I: 93 PM:1305696
289.
Messing EM, Reznikoff CA (1992) Epidermal growth factor and its receptor: markers of–and targets for–chemoprevention of bladder cancer. J Cell Biochem Suppl 16I: 56 PM:1305689
290.
Neal DE, Mellon K (1992) Epidermal growth factor receptor and bladder cancer: a review. Urol Int 48(4):365 PM:1357809
291.
Theodorescu D, Laderoute KR, Calaoagan JM, Guilding KM (1998) Inhibition of human bladder cancer cell motility by genistein is dependent on epidermal growth factor receptor but not p21ras gene expression. Int J Cancer 78(6):775 PM:9833772
292.
Liang YC, Huang YT, Tsai SH, Lin-Shiau SY, Chen CF, Lin JK (1999) Suppression of inducible cyclooxygenase and inducible nitric oxide synthase by apigenin and related flavonoids in mouse macrophages. Carcinogenesis 20(10):1945 PM:10506109
293.
Akarasereenont PC, Techatraisak K, Thaworn A, Chotewuttakorn S (2002) The expression of COX-2 in VEGF-treated endothelial cells is mediated through protein tyrosine kinase. Mediators Inflamm 11(1):17 PM:11926591
294.
Ebisuno S, Inagaki T, Kohjimoto Y, Ohkawa T (1997) The cytotoxic effect of fleroxacin and ciprofloxacin on transitional cell carcinoma in vitro. Cancer 80(12):2263 PM:9404703
295.
Seay TM, Peretsman SJ, Dixon PS (1996) Inhibition of human transitional cell carcinoma in vitro proliferation by fluoroquinolone antibiotics. J Urol 155(2):757 PM:8558720
296.
Kamat AM, Lamm DL (2004) Antitumor activity of common antibiotics against superficial bladder cancer. Urology 63(3):457 PM:15028437
297.
Ruggeri BA, Robinson C, Angeles T, Jt Wilkinson, Clapper ML (2002) The chemopreventive agent oltipraz possesses potent antiangiogenic activity in vitro, ex vivo, and in vivo and inhibits tumor xenograft growth. Clin Cancer Res 8(1):267–274PubMed
298.
Kensler T, Styczynski P, Groopman J, Helzlsouer K, Curphey T, Maxuitenko Y, Roebuck BD (1992) Mechanisms of chemoprotection by oltipraz. J Cell Biochem Suppl 16I:167–172PubMed
299.
Kensler TW, Helzlsouer KJ (1995) Oltipraz: clinical opportunities for cancer chemoprevention. p. J Cell Biochem Suppl 22:101–107PubMed
300.
Herr HW (2006) Transurethral resection of bladder tumors, in Textbook of Bladder Cancer. In: Seth P Lerner MPS, Cora N Steinberg (eds) Taylor & Francis, Abingdon, United Kingdom
301.
Grimm MO (2003) Steinhoff C, Simon X, Spiegelhalder P, Ackermann R, Vogeli TA, Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol 170(2 Pt 1):433–437
302.
Herr HW (1999) The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 162(1):74–76PubMed
303.
Dutta SC, Smith JA Jr, Shappell SB, Coffey CS, Chang SS, Cookson MS (2001) Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol 166(2):490–493PubMed
304.
Quayle SS, Ames CD, Lieber D, Yan Y, Landman J (2005) Comparison of optical resolution with digital and standard fiberoptic cystoscopes in an in vitro model. Urology 66(3):489–493PubMed
305.
Kriegmair M, Baumgartner R, Knuechel R, Steinbach P, Ehsan A, Lumper W, Hofstadter F, Hofstetter A (1994) Fluorescence photodetection of neoplastic urothelial lesions following intravesical instillation of 5-aminolevulinic acid. Urology 44(6):836–841PubMed
306.
Zaak D, Hungerhuber E, Schneede P, Stepp H, Frimberger D, Corvin S, Schmeller N, Kriegmair M, Hofstetter A, Knuechel R (2002) Role of 5-aminolevulinic acid in the detection of urothelial premalignant lesions. Cancer 95(6):1234–1238PubMed
307.
Kriegmair M, Zaak D, Stepp H, Stepp H, Baumgartner R, Knuechel R, Hofstetter A (1999) Transurethral resection and surveillance of bladder cancer supported by 5-aminolevulinic acid-induced fluorescence endoscopy. Eur Urol 36(5):386–392PubMed
308.
Zaak D, Frimberger D, Stepp H, Wagner S, Baumgartner R, Schneede P, Siebels M, Knuchel R, Kriegmair M, Hofstetter A (2001) Quantification of 5-aminolevulinic acid induced fluorescence improves the specificity of bladder cancer detection. J Urol 166(5):1665–1668; discussion 1668–1669
309.
Kriegmair M, Zaak D, Rothenberger KH, Rassweiler J, Jocham D, Eisenberger F, Tauber R, Stenzl A, Hofstetter A (2002) Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy. J Urol 168(2):475–478PubMed
310.
Filbeck T, Pichlmeier U, Knuechel R, Wieland WF, Rossler W (2003) Reducing the risk of superficial bladder cancer recurrence with 5-aminolevulinic acid-induced fluorescence diagnosis. Results of a 5-year study. Urologe A 42(10):1366–1373PubMed
311.
Daniltchenko DI, Riedl CR, Sachs MD, Koenig F, Daha KL, Pflueger H, Loening SA, Schnorr D (2005) Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. J Urol 174(6):2129–2133, discussion 2133
312.
Herr H, Tumor recurrence and progression after one versus two transurethral resection and BCG therapy (unpublished data)
313.
Herr H (2005) Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy. J Urol 174(6):2134
314.
Klan R, Loy V, Huland H (1991) Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder. J Urol 146(2):316 PM:1856924
315.
Solsona E, Iborra I, Ricos JV, Monros JL, Casanova J, Dumont R (1999) Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. J Urol 161(4):1120 PM:10081851
316.
Burnand KG, Boyd PJ, Mayo ME, Shuttleworth KE, Lloyd-Davies RW (1976) Single dose intravesical thiotepa as an adjuvant to cystodiathermy in the treatment of transitional cell bladder carcinoma. Br J Urol 48(1):55 PM:817761
317.
Oosterlinck W, Kurth KH, Schroder F, Bultinck J, Hammond B, Sylvester R (1993) A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 149(4):749 PM:8455236
318.
li-El-Dein B, Nabeeh A, el-Baz M, Shamaa S, Ashamallah A (1997) Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: a prospective, randomized controlled study. Br J Urol 79(5):731 PM:9158511
319.
Shuin T, Kubota Y, Noguchi S, Hosaka M, Miura T, Kondo I, Fukushima S, Ishizuka E, Furuhata A, Moriyama M (1994) A phase II study of prophylactic intravesical chemotherapy with 4'-epirubicin in recurrent superficial bladder cancer: comparison of 4'-epirubicin and adriamycin. Cancer Chemother Pharmacol 35 Suppl:S52 PM:7994787
320.
Tolley DA, Parmar MK, Grigor KM, Lallemand G, Benyon LL, Fellows J, Freedman LS, Grigor KM, Hall RR, Hargreave TB, Munson K, Newling DW, Richards B, Robinson MR, Rose MB, Smith PH, Williams JL, Whelan P (1996) The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol 155(4):1233 PM:8632538
321.
Dalbagni G, Herr HW (2000) Current use and questions concerning intravesical bladder cancer group for superficial bladder cancer. Urol Clin North Am 27(1):137 PM:10696252
322.
Duque JL, Loughlin KR (2000) An overview of the treatment of superficial bladder cancer. Intravesical chemotherapy. Urol Clin North Am 27(1):125 PM:10696251
323.
Sylvester RJ, van der Meijden AP, Lamm DL (2002) Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168(5):1964 PM:12394686
324.
Sylvester RJ, Oosterlinck W, van der Meijden AP (2004) A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 171(6 Pt 1):2186 PM:15126782
Metadata
Title
Chemoprevention of bladder cancer
Authors
Dragan J. Golijanin
David Kakiashvili
Ralph R. Madeb
Edward M. Messing
Seth P. Lerner
Publication date
01-11-2006
Publisher
Springer-Verlag
Published in
World Journal of Urology / Issue 5/2006
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-006-0123-x

Other articles of this Issue 5/2006

World Journal of Urology 5/2006 Go to the issue

Topic Paper

Improving outcomes with radical cystectomy for high-grade invasive bladder cancer

Topic Paper

Use of nomograms as predictive tools in bladder cancer

Topic Paper

Bladder-sparing approaches to invasive disease

Topic Paper

Treatment options for BCG failures

Original Article

Morbidity associated with repeated transrectal high-intensity focused ultrasound treatment of localized prostate cancer

Original Article

Chemopreventive property of dietary ginger in rat urinary bladder chemical carcinogenesis